ITOC 2020 | ADAR inhibition: patient stratification

Jeffrey Ishizuka, MD, DPhil, Yale School of Medicine, New Haven, CT, discusses what patients would benefit the most from ADAR inhibition therapy. He considers the mechanisms that will trigger an improved immune response and concludes that patients with low levels of T-cells within the tumor microenvironment and loss of MHC-I would benefit from ADAR inhibition. This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.